Related Experiment Video

Updated: Jun 15, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

[Prophylaxis of hepatitis B in children treated for ALL]

Małgorzata Krupa1, Tomasz Szczepański

  • 1Katedra i Klinika Pediatrii, Hematologii i Onkologii Dzieciecej SUM, Samodzielny Publiczny Szpital Kliniczny Nr 1 w Zabrzu.

Wiadomosci Lekarskie (Warsaw, Poland : 1960)
|March 17, 2010
PubMed

Insights

Hepatitis B virus (HBV) prophylaxis effectively protected children with acute lymphoblastic leukemia (ALL) from new infections. All patients maintained protective anti-HBV titers or avoided infection despite varying prophylaxis strategies during ALL treatment.

Area of Science:

  • Pediatric Oncology
  • Immunology
  • Infectious Diseases

Context:

  • Acute lymphoblastic leukemia (ALL) is a common childhood cancer.
  • ALL treatment often causes immunodeficiency, increasing infection risk.
  • Hepatitis B virus (HBV) infection is a significant concern for these vulnerable patients.

Purpose:

  • To evaluate the effectiveness of hepatitis B virus (HBV) prophylaxis in children undergoing treatment for acute lymphoblastic leukemia (ALL).
  • To assess HBV infection rates and anti-HBV antibody titers in pediatric ALL patients receiving different prophylaxis regimens.

Summary:

  • A study of 66 children with ALL investigated HBV prophylaxis strategies.
  • Patients were grouped based on vaccination status before diagnosis and received various prophylaxis post-diagnosis.
  • All patients achieved protective anti-HBV titers or remained free from de novo HBV infection, indicating successful prophylaxis.

Impact:

  • Demonstrates that comprehensive HBV prophylaxis is effective in preventing new HBV infections in immunocompromised children with ALL.
  • Highlights the importance of tailored HBV prophylaxis protocols for pediatric cancer patients.
  • Contributes to improved management strategies for infectious complications in pediatric oncology.
Abstract

More Related Videos

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Transmission-based Precautions I: Contact, Enteric, and Droplets01:17

Transmission-based Precautions I: Contact, Enteric, and Droplets

Transmission-based precautions are for patients known to be infected or suspected to be infected or colonized with organisms that pose a significant risk to others. Some transmission-based precautions include contact, enteric, and droplet.
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...
Standard Precaution01:26

Standard Precaution

Standard precautions are the minimum infection control safeguards used while caring for all patients, irrespective of their disease condition. They help prevent the spread of common infectious microorganisms to healthcare workers, patients, and visitors in all healthcare settings.
Hand hygiene is the most crucial means to prevent the transmission of disease. Employers are legally required to provide their workers with personal protective equipment (PPE) to minimize exposure or contact with...